aNHEJ	alternative non-homologous end-joining
BER	base excision repair
BID	bis in die, twice a day
BRCA1/2	breast cancer type 1/type 2 susceptibility protein
CNA	copy number alterations
CAT	catalytic domain (of PARP-1)
CBR	clinical benefit rate
CGH	comparative genomic hybridization
CR	complete response
DLT	dose-limiting toxicities
DNMTi	DNA methyltransferase inhibitor
DSB	double-strand break
EMI1	early mitotic inhibitor 1
ER	estrogen receptor
EZH2	enhancer of zeste homolog 2
gBRCAm	germline BRCA mutation-associated
HD	helical domain
HER2	human epidermal growth factor receptor 2
HRD	homologous recombination deficiency/homologous recombination-deficient
HR	hormone receptor
HRR	homologous recombination repair
IRIF	ionizing radiation induced foci
IV	intravenous
LOH	loss of heterozygosity
LST	large-scale state transitions
miRNA	micro RNA
NAD+	nicotinamide adenine dinucleotide
NHEJ	non-homologous end-joining
ORR	objective response rate
PARP	poly (ADP-ribose) polymerase
PARPi	poly (ADP-ribose) polymerase inhibitor
pCR	pathological complete response
PCT	physician’s choice of chemotherapy
PFS	progression-free survival
PO	per os, by mouth
PR	progesterone receptor
PRC2	polycomb repressive complex 2
PRR	partial response rate
QD	quaque die, once a day
RER	ribonucleotide excision repair
ROS	reactive oxygen species
RP2D	recommended phase 2 dose
SD	stable disease
SNP	single-nucleotide polymorphism
SSA	single-strand annealing
TAI	telomeric allelic imbalance
TNBC	triple negative breast cancer
TOP1	topoisomerase 1